natgillin/translations-raw huggingface dataset:
This study showed that, overall, the lincomycin-spectinomycin combination significantly improved the tested clinical, pathological and bacteriological endpoints in an experimental model of aerosol infection, at a dose of 16.65 mg lincomycin and 33.35 mg spectinomycin/kg bw (50 mg combined actives/kg bw) per day for 7 days.
Ta študija je dokazala, da je kombinacija linkomicina in spektinomicina v odmerku 16,65 mg linkomicina in 33,35 mg spektinomicina na kg telesne mase (50 mg kombiniranih zdravilnih učinkovin na kilogram telesne mase) na dan s časom zdravljenja sedem dni v splošnem pomembno izboljšala preskušane klinične, patološke in bakteriološke končne točke v poskusnem modelu okužbe z aerosoli.
Powder to be administered with the feed
prašek za dajanje v krmo
222 mg 444,7 mg
222 mg 444,7 mg prašiči, piščanci
Pigs, chickens
prašiči, piščanci
222 mg 444 mg
222 mg 444 mg prašiči, piščanci
Linco-Spectin 100, 222 + 444,7 mg/g pó para administração na água de bebida para suínos e galinhas
Linco-Spectin 100, 222 + 444,7 mg/g pó para administração na água de bebida para suínos e galinhas prašiči, piščanci
Very limited data or no data were provided to support the use of premixes for medicated feeding stuff and oral powders to be administered with the feed containing lincomycin and spectinomycin.
V podporo uporabi predmešanic za zdravilno krmno mešanico in peroralnih praškov za dajanje v krmo, ki vsebujejo linkomicin in spektinomicin, so bili predloženi zelo omejeni podatki ali pa jih sploh ni bilo.
Piglets, calves, chickens
Micospectone prašički, teleta, piščanci
Linco-Spectin 100, 222/444.7 mg/g Powder for Use in Drinking Water for Pigs and Chickens
Linco-Spectin 100, 222/444.7 mg/g Powder for use in drinking water for pigs and chickens prašiči, piščanci
Linco-Spectin 100, 222/444.7 mg/g Powder for use in drinking water for pigs and chickens
Linco-Spectin 100, 222/444.7 mg/g Powder for Use in Drinking Water for Pigs and Chickens prašiči, piščanci
Calves, piglets, chickens
Pyanosid Pulver prašiči, piščanci
End of February
Konec februarja
The mechanism of action is multifactorial.
Mehanizem delovanja je multifaktorski.
However, the clinical relevance of these findings is unknown.
Vendar klinična pomembnost teh ugotovitev ni znana.
Updated analysis from CIBMTR to be submitted by end of December 2020.
CIBMTR je treba predložiti do konca decembra 2020.
# median (min-max)
# mediana (min-maks)
However, the exact mechanism of action of defibrotide is not fully elucidated.
Vendar natančni mehanizem delovanja defibrotida ni popolnoma pojasnjen.
You will receive this treatment four times a day for at least 21 days or until your symptoms resolve.
To zdravljenje boste prejemali štirikrat na dan vsaj 21 dni ali dokler simptomi ne izginejo.
Absorption and Distribution
Absorpcija in porazdelitev
Almost all renal excretion occurs within the first 4 hours.
Skoraj vse izločanje skozi ledvice nastopi v prvih 4 urah.
This can be caused by medicines that are given prior to a stem cell transplantation.
To lahko povzročijo zdravila, ki se dajejo pred presaditvijo matičnih celic.
Individual Studies
Posamezne študije
Safety information in children are available from the prevention study conducted solely in children.
Varnostni podatki pri otrocih so na voljo iz preventivne študije, ki so jo opravili samo pri otrocih.
At an interim analysis of the on-going registry, data from 96 patients with severe VOD were available.
Pri vmesni analizi potekajočega registra so bili na voljo podatki za 96 bolnikov s hudo VOB.
Summary of the Safety Profile
Povzetek varnostnega profila
It will be slowly injected (over a 2-hour period) into one of your veins.
Počasi vam ga bodo injicirali (v 2 urah) v eno od ven.
Data derived from an independent US registry have shown a beneficial effect of Defitelio in routine clinical practice.
Podatki iz neodvisnega registra ZDA so pokazali koristen učinek zdravila Defitelio v rutinski klinični praksi.
Historical Control
Zgodovinska kontrola
As you will be given this medicine by a doctor or a nurse it is unlikely that a dose will be missed.
Ker vam bo to zdravilo dajal zdravnik ali medicinska sestra, ni verjetno, da bi bil odmerek izpuščen.
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded in the patient file.
Za izboljšanje sledljivosti bioloških zdravil je treba ime in številko serije uporabljenega zdravila jasno zapisati v bolnikovo kartoteko.
• if you have problems with blood circulation because your body cannot maintain a constant blood pressure.
• če imate težave s krvnim obtokom, ker telo ni zmožno vzdrževati stalnega krvnega tlaka.
This is called an ‘intravenous infusion' or drip.
To se imenuje »intravensko infundiranje« ali infuzija.
MARKETING AUTHORISATION NUMBER(S) EU/1/13/878/001
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/13/878/001
In the treatment studies over 50% of the patients were children.
V študijah zdravljenja je bilo več kot 50 % bolnikov otrok.
This leaflet was last revised in:
Navodilo je bilo nazadnje revidirano dne :
However there was no difference in incidence of serious bleeding or bleeding events with fatal outcome.
Vendar pa ni bilo razlike v pojavnosti resnih dogodkov krvavitve ali krvavitve s smrtnim izidom.
Frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000).
Pogostnost je opredeljena kot: zelo pogosti (≥ 1/10); pogosti (≥1/100 do <1/10), občasni (≥1/1.000 do <1/100), redki (≥1/10.000 do <1/1.000), zelo redki (<1/10.000).
Table 1: Treatment Study Results: Complete Response and Survival Rate of Severe VOD at Day+100
Preglednica 1: Rezultati študije zdravljenja: popoln odziv in stopnja preživetja pri hudi VOB po 100.+ dnevu
• if you are using other medicines to break down blood clots such as tissue plasminogen activator
• če uporabljate druga zdravila za razgrajevanje krvnih strdkov, kot je tkivni aktivator plazminogena.
Date of latest renewal: 26 July 2018
Datum prve odobritve: 18. oktober 2013 Datum zadnjega podaljšanja: 26. julija 2018
• if you are allergic to defibrotide or any of the other ingredients of this medicine (listed in section 6)
• če ste alergični na defibrotid ali katero koli sestavino tega zdravila (navedeno v poglavju 6);
• severe allergic reaction (you might experience swelling of the hands, face, lips, tongue or throat,
• huda alergijska reakcija (pojavita se lahko otekanje dlani, obraza, ustnic, jezika ali grla in oteženo dihanje).
If particles are observed and/or the liquid in the vial is not clear, the vial must not be used.
Če opazite delce in/ali tekočina v viali ni bistra, viale ne smete uporabiti.
• if you are taking medicine that increases the risk of bleeding
• če jemljete zdravila, ki povečujejo tveganje za krvavitev;
If you are sexually active and you or your partner could become pregnant, you both must use effective contraception during treatment with Defitelio and for 1 week after stopping the treatment.
Če ste spolno dejavni in lahko vi ali vaša partnerka zanosite, morata oba uporabljati učinkovito kontracepcijo med zdravljenjem z zdravilom Defitelio in 1 teden po prekinitvi zdravljenja.
Considering the nature of the medicinal product, a risk to the newborns/infants is not expected.
Glede na naravo zdravila tveganja za novorojenčke/dojenčke ni pričakovati.
The report will also reflect on the safety data being collected during prophylactic treatment, and any potential safety differences related to the difference in indication (ie treatment vs prophylactic therapy).
Poročilo bo odražalo tudi podatke o varnosti, ki se zbirajo med profilaktičnim zdravljenjem, in morebitne razlike v varnosti, povezane z razliko v indikaciji (npr. pri zdravljenju v primerjavi s profilaktičnim zdravljenjem).
Additional information is shown in the following Table 2.
Dodatni podatki so prikazani v spodnji preglednici 2.
PAI-2 is known to be uniquely up-regulated in the placenta.
Znano je, da se raven zaviralca PAI-2 edinstveno viša v placenti.
4.5 Interaction with other medicinal products and other forms of interaction Potential interactions with recombinant t-PA
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Morebitne interakcije z rekombinantnim t-PA
The recommended dose in children from one month to 18 years of age is the same as in adults.
Priporočeni odmerek pri otrocih, starih od enega meseca do 18 let, je enak kot pri odraslih.
No special precautions are indicated.
Potrebni niso nobeni posebni previdnostni ukrepi.
In each of the clinical trials performed in the treatment of VOD, over 50% of patients were under the age of 18 years.
V vseh kliničnih preskušanjih, opravljenih pri zdravljenju VOB, je bilo več kot 50 % bolnikov starih manj kot 18 let.
Volume of distribution is around 10 L. In vitro studies demonstrate that 93% of Defitelio is bound to plasma proteins.
Prostornina porazdelitve je približno 10 l. Študije in vitro so pokazale, da se 93 % zdravila Defitelio veže na beljakovine v plazmi.
Marketing Authorisation Holder and Manufacturer Gentium Srl
Imetnik dovoljenja za promet z zdravilom in izdelovalec Gentium Srl
Use of medicinal products that increase the risk of haemorrhage within 24 hours of Defitelio administration (within 12 hours in the case of unfractionated heparin) is not recommended.
Uporaba zdravil, ki povečajo tveganje krvavitve, v 24 urah po uporabi zdravila Defitelio (v 12 urah pri nefrakcioniranem heparinu) ni priporočljiva.
The treatment with Defitelio can be initiated and continuously supervised only by an experienced doctor in a hospital or in a specialised centre for stem cells transplantation.
Zdravljenje z zdravilom Defitelio lahko uvede in stalno nadzoruje samo izkušen zdravnik v bolnišnici ali specializiranem centru za presaditev matičnih celic.
Median length of therapy in those treated with Defitelio was 22 days.
Mediana trajanja zdravljenja bolnikov, zdravljenih z zdravilom Defitelio, je bila 22 dni.
PHARMACEUTICAL FORM AND CONTENTS Concentrate for solution for infusion 10 vials
FARMACEVTSKA OBLIKA IN VSEBINA koncentrat za raztopino za infundiranje 10 vial
There is no specific antidote for overdose and treatment should be symptomatic.
Za preveliko odmerjanje ni posebnega antidota, zato mora biti zdravljenje simptomatsko.
Macrophages are considered the main target organ.
Domnevajo, da so makrofagi glavni tarčni organ.
However, if used, in exceptional cases, caution should be exercised by closely monitoring the coagulation parameters (see section 4.4).
Če pa se sočasno uporabljajo v izjemnih primerih, je treba biti previden in skrbno spremljati parametre koagulacije (glejte poglavje 4.4).
The efficacy and safety of defibrotide in the treatment of severe VOD were studied in a pivotal Phase 3 historical-controlled study (2005-01).
Učinkovitost in varnost defibrotida pri zdravljenju hude VOB so preučevali v ključni, zgodovinsko nadzorovani študiji 3. faze (2005-1).
* produced from porcine intestinal mucosa.
* Izdelanega iz prašičje črevesne sluznice.
• if you have heavy bleeding and need a blood transfusion
• če imate močno krvavitev, ki zahteva transfuzijo krvi;
Preparation of Defitelio (use aseptic technique):
Priprava zdravila Defitelio (z aseptično tehniko):
For adverse reactions reported in both studies, the highest frequency was used in the table below.
Za neželene učinke, o katerih so poročali v obeh študijah, je v spodnji preglednici uporabljena njihova največja pogostnost.
The treatment should be administered for a minimum of 21 days and continued until the symptoms and signs of severe VOD resolve.
Zdravilo je treba uporabljati najmanj 21 dni, zdravljenje pa mora trajati, dokler simptomi in znaki hude VOB ne izginejo.
• coagulopathy (disturbance of blood clotting)
• koagulopatija (motnja strjevanja krvi),
It is not known whether defibrotide is excreted in human milk.
Ni znano, ali se defibrotid izloča v materino mleko.
The concentrate solution for infusion has to be diluted using aseptic technique.
Koncentrat za raztopino za infundiranje je treba razredčiti z aseptično tehniko.
These data are from an open label registry and the subjects were not randomised.
Ti podatki izhajajo iz odprtega registra, pri katerem preskušanci niso bili naključno razporejeni.
Once diluted for use the infusion storage should not exceed 24 hours at 2°C -8°C unless dilution has taken place in controlled and validated aseptic conditions.
Po redčenju za uporabo čas shranjevanja infuzije ne sme preseči 24 ur pri temperaturi 2-8 °C, razen če je bilo redčenje opravljeno pri nadzorovanih in validiranih aseptičnih pogojih.
Pack size of 10 vials.
Velikost pakiranja: 10 vial.
The frequency nature and severity of adverse reactions in children are otherwise the same as in adults.
Pogostnost in resnost neželenih učinkov pri otrocih sta enaki kot pri odraslih.
Defibrotide does not inhibit or induce CYP450s.
Defibrotid ne zavira in ne inducira encimov CYP450.
Pharmacotherapeutic group: other antithrombotic agents; ATC code: B01AX01.
Farmakoterapevtska skupina: Druge antitrombotične učinkovine, oznaka ATC: B01AX01 Mehanizem delovanja
Do not use Defitelio after the expiry date which is stated on the carton and vial label after EXP.
Zdravila Defitelio ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in nalepki viale poleg oznake »EXP«.
It primarily acts through reducing excessive endothelial cell (EC) activation (endothelial dysfunction), modulating endothelial homeostasis as well as restoring thrombo-fibrinolytic balance.
Primarno deluje tako, da zmanjša pretirano aktivacijo endotelijskih celic (EC) (endotelijska disfunkcija), modulira endotelijsko hemostazo, pa tudi obnavlja trombo-fibrinolitično ravnovesje.
Vials are intended for a single use and unused solution from a single dose must be discarded (see section 6.6)
Viale so namenjene enkratni uporabi, zato je treba neporabljeno raztopino iz enkratnega odmerka zavreči (glejte poglavje 6.6).
Adverse reactions observed are listed below, by system organ class and frequency.
Spodaj so navedeni opaženi neželeni učinki glede na organski sistem in pogostnost.
*=Kaplan Meier estimates for time-to-event analysis by Day100
* Kaplan-Meierjeve ocene za analizo časa do dogodka do 100.+ dneva.
OTHER 200 mg/2.5 mL Gentium Srl
DRUGI PODATKI 200 mg/2.5 mL Gentium Srl
The safety data from the pivotal study are supported and confirmed with data from the completed Treatment-IND study.
Podatke o varnosti iz ključne študije podpirajo in potrjujejo podatki iz končane študije T-IND.
Defitelio should always be diluted prior to use.
Zdravilo Defitelio je treba pred uporabo vedno razredčiti.
Defibrotide works by protecting the cells of the blood vessels and preventing or breaking down the blood clots.
Defibrotid deluje tako, da zaščiti celice krvnih žil in prepreči ali razgradi krvne strdke.
2.5 mL vials (Type I clear glass), closed with a stopper (butyl rubber) and seal (aluminium).
2,5-mililitrske viale (prozorno steklo tipa I), zaprte z zamaškom (butilna guma) in tesnilom (aluminij).
Accumulation of defibrotide over 4 doses was not found.
Kopičenja defibrotida po 4 odmerkih niso ugotovili.
The required volume from the Defitelio vials should be withdrawn and combined.
Izvleči je treba potrebno prostornino zdravila Defitelio in jo združiti.
There are no studies investigating the effects of defibrotide on human fertility.
Študij o učinkih defibrotida na plodnost pri človeku ni.
Therefore, the use of defibrotide with antithrombotic/fibrinolytic medicinal products is not recommended.
Uporaba defibrotida z antitrombotičnimi/fibrinolitičnimi zdravili zato ni priporočljiva.
It is administered by intravenous infusion, over two hours.
Daje se z intravenskim infundiranjem, ki traja dve uri.
The use of Defitelio rescue treatment for all patients who developed VOD meant that the study was not designed to assess any survival advantage and none was seen in this study.
Uporaba reševalnega zdravljenja z zdravilom Defitelio pri vseh bolnikih, pri katerih se je razvila VOB, pomeni, da študija ni bila zasnovana za ocenjevanje kakršne koli prednosti pri preživetju, česar tudi niso opazili.
The Day+100 all-cause mortality in patients with severe VOD who were not treated with defibrotide was 69%, and 61% in those patients who received defibrotide.
Umrljivost zaradi vseh vzrokov pri bolnikih s hudo VOB, ki se niso zdravili z defibrotidom, je bila 100.+ dan 69-odstotna, pri bolnikih, ki so prejemali defibrotid, pa 61-odstotna.
The efficacy data from this pivotal study are supported and confirmed with data from a dose-finding study (25 mg/kg arm) and the Open Label Treatment-IND study, as presented in Tables 1.
Podatke o učinkovitosti iz te ključne študije podpirajo in potrjujejo podatki iz študije za ugotavljanje odmerka (skupina s 25 mg/kg) in podatki iz odprte študije zdravljenja IND, kot je predstavljeno v preglednici 1.
• The active substance is defibrotide.
• Učinkovina je defibrotid.
Administration of defibrotide to patients who have haemodynamic instability, defined as inability to maintain mean arterial pressure with single pressor support, is not recommended.
Uporaba defibrotida pri bolnikih s hemodinamsko nestabilnostjo, opredeljeno kot nezmožnost vzdrževanja povprečnega arterijskega tlaka ob podpori z enim presorjem, ni priporočljiva.
Defitelio may be used during breastfeeding.
Zdravilo Defitelio se lahko uporablja med dojenjem.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not normally be expected to exceed 24 hours at 2-8°C.
Če se zdravilo ne porabi takoj, je uporabnik odgovoren za čas in pogoje shranjevanja pred uporabo, to pa ne bi smelo trajati dlje kot 24 ur pri temperaturi 2-8 C.
Only clear solutions without visible particles should be used.
Uporabiti smete samo prozorno raztopino brez vidnih delcev.
For patients treated with Defitelio the following side effects were reported.
Pri bolnikih, zdravljenih z zdravilom Defitelio, so poročali o naslednjih neželenih učinkih.
Based on the results of the QTc study, conducted in healthy subjects at therapeutic and supra-therapeutic doses, it can be concluded that Defitelio has no significant or clinically relevant QTc-prolonging potential at doses up to 4 times higher than therapeutically indicated.
Na podlagi rezultatov študije QTc, opravljene pri zdravih preskušancih s terapevtskimi in supraterapevtskimi odmerki, lahko sklepamo, da zdravilo Defitelio nima statistično ali klinično pomembnega potenciala za podaljšanje QTc pri odmerkih, do 4-krat večjih od terapevtsko indiciranih.
In patients who have or develop clinically significant acute bleeding requiring blood transfusion, Defitelio is not recommended or should be discontinued.
Pri bolnikih, ki imajo klinično pomembno akutno krvavitev, ki zahteva krvno transfuzijo, zdravilo Defitelio ni priporočljivo ali pa je treba njegovo uporabo prekiniti.
Potential interactions with antithrombotic fibrinolytic agents Defibrotide has a profibrinolytic effect (see section 5.1) and this may potentially enhance the activity of antithrombotic/fibrinolytic medicinal products.
Morebitne interakcije z antitrombotičnimi fibrinolitičnimi učinkovinami Defibrotid ima profibrinolitičen učinek (glejte poglavje 5.1), kar lahko okrepi delovanje antitrombotičnih/fibrinolitičnih zdravil.
Forty-four children and 58 adult patients with severe VOD post-HSCT, were treated with Defitelio 25 mg/kg/day intravenous by infusion, and compared with 32 historical control patients.
Štiriinštirideset otrok in 58 odraslih bolnikov s hudo VOB po PKMC so zdravili z zdravilom Defitelio v odmerku 25 mg/kg/dan, danim intravensko z infundiranjem, potem pa so jih primerjali z 32 zgodovinskimi kontrolnimi bolniki.
What you need to know before you take Defitelio
Kaj morate vedeti, preden boste prejeli zdravilo Defitelio
It is recommended that the diluted Defitelio solution be administered to patients using an infusion set equipped with a 0.2 μm in-line filter.
Priporočljivo je, da razredčeno raztopino zdravila Defitelio bolnikom aplicirate s kompletom za infundiranje, opremljenim z vgrajenim 0,2-μm filtrom.
This means that due to the rarity of the disease and for ethical reasons preventing to perform a placebo-controlled study, it has not been possible to obtain complete information on this medicinal product.
To pomeni, da zaradi redkosti bolezni in iz etičnih razlogov, ki so preprečili izvajanje s placebom nadzorovane študije, ni bilo mogoče pridobiti vseh podatkov o zdravilu.
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal products subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE Predpisovanje in izdaja zdravila je le na recept s posebnim režimom (glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
The number of vials to be diluted should be determined based on the individual patient's weight (see section 4.2).
Število vial, ki jih je treba razredčiti, je treba določiti na podlagi posameznikove telesne mase (glejte poglavje 4.2).
In addition, Day+100 survival rate was improved in the Defitelio group with 38.2% (39/102) of the patients surviving versus 25.0% (8/32) in the historical control group (p=0.034).
Poleg tega se je po 100.+ dnevu izboljšal delež preživetja v skupini z zdravilom Defitelio, v kateri je preživelo 38,2 % bolnikov (39/102), v primerjavi z zgodovinsko kontrolno skupino z deležem 25,0 % (8/32) (p = 0,034).
Patients (n=356) were randomised to receive 25 mg/kg/day from the start of conditioning or were randomised to receive no prophylaxis.
Bolniki (n = 356) so bili naključno razporejeni v skupino, ki je prejemala 25 mg/kg/dan od začetka priprav, ali v skupino brez profilakse.
Defitelio must be prescribed and administered to patients by specialised physicians experienced in the diagnosis and treatment of complications of HSCT.
Zdravilo Defitelio mora bolnikom predpisati in dajati specialist z izkušnjami z diagnosticiranjem ter zdravljenjem zapletov PKMC.
In the paediatric prevention study at 25 mg/kg/day there was an increased incidence of any bleeding events in the defibrotide group compared with the treatment group.
V pediatrični preventivni študiji z odmerkom 25 mg/kg/dan so opazili povečano pojavnost katerih koli dogodkov krvavitve v skupini z defibrotidom v primerjavi s skupino, ki se je zdravila.
The recommended dose for children aged 1 month to 18 years is the same mg/kg dose as for adults i.e. 6.25 mg/kg body weight every 6 hours.
Priporočeni odmerek pri otrocih, starih od 1 meseca do 18 let, je enak odmerku na osnovi mg/kg kot pri odraslih, tj. 6,25 mg/kg telesne mase vsakih 6 ur.
Defitelio is for intravenous use.
Zdravilo Defitelio je za intravensko uporabo.
• localized blood collection out of the vessel (hematoma) in the brain
• lokalizirano nabiranje krvi zunaj žile (hematom) v možganih,
Concomitant systemic anticoagulant therapy (e.g. heparin, warfarin, direct thrombin inhibitors and direct factor Xa inhibitors) (see section 4.5), except for routine maintenance or reopening of central venous line, requires careful monitoring.
Sočasno zdravljenje s sistemskimi antikoagulanti (npr. heparinom, varfarinom, direktnimi zaviralci trombina in direktnimi zaviralci faktorja Xa) (glejte poglavje 4.5), z izjemo rednega vzdrževanja ali vnovičnega odpiranja centralne venske linije, zahteva skrbno spremljanje.
Side effects in children (1 month to 18 years old) are expected to be similar in type, severity and frequency and no other special precautions are needed.
Pričakovano je, da bodo vrsta, resnost in pogostnost neželenih učinkov pri otrocih (od 1 meseca do 18 let) podobni kot pri odraslih, zato niso potrebni nobeni drugi posebni previdnostni ukrepi.
Defibrotide is an oligonucleotide mixture with demonstrated antithrombotic, fibrinolytic, anti-adhesive and anti-inflammatory actions.
Defibrotid je mešanica oligonukleotidov z dokazanim antitrombotičnim, fibrinolitičnim, antiadhezivnim in protivnetnim delovanjem.